OBJECTIVE: Evaluate and compare the effectiveness of CA125, HE4, Mesothelin and MMP7 marker levels to monitor ovarian cancer patients after surgery and chemotherapy. Evaluate the lead time of a rise of marker levels before recurrence. METHODS: The study consists of 23 patients with advanced stage ovarian/fallopian tube cancer. Blood was drawn after front line surgery and chemotherapy treatment and at 3 month intervals thereafter. One patient had chemoresistant disease, two patients remained in remission and 20 patients had recurring disease and were used for marker evaluation. RESULTS: In five patients HE4 was the only marker to elevate before recurrence with a lead time of up to 4½ months including one patient who did not have a CA125 response at all. In a further two patients, HE4 increased before CA125 did. In four of these seven patients, HE4 levels were consistently at or above threshold during remission when both CA125 and imaging results were negative. MMP7 elevated before recurrence in one patient who was negative for the other markers. Mesothelin elevated in two patients who were also positive for CA125 and HE4. CONCLUSIONS: HE4 can predict ovarian cancer recurrence earlier than CA125 and it can be elevated in patients that do not express CA125 at sufficient levels to make a clinical decision. MMP7 and Mesothelin have lower potential as markers for ovarian cancer recurrence to complement CA125. A failure of HE4 levels to normalize at completion of standard therapy may indicate a poor prognosis. Copyright Â
OBJECTIVE: Evaluate and compare the effectiveness of CA125, HE4, Mesothelin and MMP7 marker levels to monitor ovarian cancerpatients after surgery and chemotherapy. Evaluate the lead time of a rise of marker levels before recurrence. METHODS: The study consists of 23 patients with advanced stage ovarian/fallopian tube cancer. Blood was drawn after front line surgery and chemotherapy treatment and at 3 month intervals thereafter. One patient had chemoresistant disease, two patients remained in remission and 20 patients had recurring disease and were used for marker evaluation. RESULTS: In five patientsHE4 was the only marker to elevate before recurrence with a lead time of up to 4½ months including one patient who did not have a CA125 response at all. In a further two patients, HE4 increased before CA125 did. In four of these seven patients, HE4 levels were consistently at or above threshold during remission when both CA125 and imaging results were negative. MMP7 elevated before recurrence in one patient who was negative for the other markers. Mesothelin elevated in two patients who were also positive for CA125 and HE4. CONCLUSIONS:HE4 can predict ovarian cancer recurrence earlier than CA125 and it can be elevated in patients that do not express CA125 at sufficient levels to make a clinical decision. MMP7 and Mesothelin have lower potential as markers for ovarian cancer recurrence to complement CA125. A failure of HE4 levels to normalize at completion of standard therapy may indicate a poor prognosis. Copyright Â
Authors: Xiaohong Chang; Xue Ye; Li Dong; Hongyan Cheng; Yexia Cheng; Lirong Zhu; Qinping Liao; Yang Zhao; Li Tian; Tianyun Fu; Jun Chen; Heng Cui Journal: Int J Gynecol Cancer Date: 2011-07 Impact factor: 3.437
Authors: Gordon J S Rustin; Maria E L van der Burg; Clare L Griffin; David Guthrie; Alan Lamont; Gordon C Jayson; Gunnar Kristensen; César Mediola; Corneel Coens; Wendi Qian; Mahesh K B Parmar; Ann Marie Swart Journal: Lancet Date: 2010-10-02 Impact factor: 79.321
Authors: Nathalie Scholler; Meghan Crawford; Alicia Sato; Charles W Drescher; Kathy C O'Briant; Nancy Kiviat; Garnet L Anderson; Nicole Urban Journal: Clin Cancer Res Date: 2006-04-01 Impact factor: 12.531
Authors: Laura J Havrilesky; Clark M Whitehead; Jennifer M Rubatt; Robert L Cheek; John Groelke; Qin He; Douglas P Malinowski; Timothy J Fischer; Andrew Berchuck Journal: Gynecol Oncol Date: 2008-06-27 Impact factor: 5.482
Authors: Beth Y Karlan; Jason Thorpe; Kate Watabayashi; Charles W Drescher; Melanie Palomares; Mary B Daly; Pam Paley; Paula Hillard; M Robyn Andersen; Garnet Anderson; Ronny Drapkin; Nicole Urban Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-05-01 Impact factor: 4.254
Authors: Dirk Bauerschlag; Karen Bräutigam; Roland Moll; Jalid Sehouli; Alexander Mustea; Darius Salehin; Maryla Krajewska; John C Reed; Nicolai Maass; Garret M Hampton; Ivo Meinhold-Heerlein Journal: J Cancer Res Clin Oncol Date: 2012-10-23 Impact factor: 4.553
Authors: Pierluigi Giampaolino; Virginia Foreste; Luigi Della Corte; Claudia Di Filippo; Giuseppe Iorio; Giuseppe Bifulco Journal: Gland Surg Date: 2020-08
Authors: Nicole Urban; Jason Thorpe; Beth Y Karlan; Martin W McIntosh; Melanie R Palomares; Mary B Daly; Pamela Paley; Charles W Drescher Journal: Cancer Epidemiol Biomarkers Prev Date: 2012-09-07 Impact factor: 4.254